Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2000

View Archived Issues

Coffee and caffeine intake and risk of Parkinson's disease

University researchers shed new light on neurodegenerative diseases

Licensing opportunity from NIH: conjugated cell toxins for chronic pain

Licensing opportunity from NIH: MRP-1 inhibitors

Genta and Molecular Biosystems establish licensing agreement for antisense technology

BioSante and Permatec enter licensing and development agreement

Lilly details late-stage product pipeline

CAT's clinical development programs continue to make good progress

BioChem Pharma and Cytovax sign collaborative agreement

Hepatocyte growth factor attenuates intimal hyperplasia in rabbit arterial injury model

NIAID awards Ixion grant to research Sjogren's syndrome diagnostic

Symbollon completes phase I trial with IoGen for treatment of fibrocystic breast disease

Fast track designation granted for OGT-918 in Gaucher's disease

OSI acquires full development and marketing rights for CP-358774/OSI-774

Vivus signs international marketing agreement for Muse and Alibra

LY-203638 effective in patients with HIT

Once-daily Ditropan XL gains marketing approval in U.K.

Aventis pipeline includes new macrolides

Monoamine reuptake inhibitors designed by Faes particularly useful as antidepressants

New compounds in development at Pharmacia for use in infectious diseases

Three newly issued patents cover novel CCR3 receptor antagonists synthesized at SmithKline Beecham

Novo Nordisk presents new agents for endocrine disorders

Design of new multitarget AIDS therapeutic with a favorable resistance profile

June meeting of GI Drugs Advisory Committee to discuss Lotronex and Zelmac

Binding and functional profile of KMD-3213 predicts low propensity for vascular side effects

In vivo activity against prostate cancer now reported for TAC-101

Favorable resistance profile of BMS-232632 further supports its potential in HIV treatment

Addition of pramlintide to insulin therapy improves metabolic control in type 1 and 2 diabetics

Major European launch for Actonel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...